Jivan Biologics awarded US patent for splice array analysis

Jivan Biologics Inc., a privately held corporation located in Berkeley, CA, has been awarded US Patent #7,340,349, "Method and System for Identifying Splice Variants of a Gene."

The issued claims cover mathematical algorithms for determining the expression levels of splice isoforms of a gene in a sample using microarrays with exon junction probes.

"The '349 Patent validates JIVAN's position as a leader in the growing market for DNA microarrays to detect alternative splicing," said Subha Srinivasan, PhD, CEO of JIVAN. "Powerful data analysis is critical to the adoption of splicing arrays, the next generation of expression arrays."

The '349 Patent fits in JIVAN's broader strategy of providing a complete solution for splice isoform expression, ranging from array design to microarray services to data analysis to PCR validation.

For more information, visit JIVAN at http://www.jivanbio.com/.

Jivan Biologics empowers scientists with new insight by providing a full catalogue of splice variant microarrays, analysis software and PCR primer designs to benefit all stages of the drug development pipeline: biomarkers in blood, diagnostics, target validation, toxicology and basic research.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New model sheds light on APOE4's role in Alzheimer's pathology